Do Institutional Investors Hate PDL Biopharma Inc (NASDAQ:PDLI)?

October 2, 2018 - By Peter Kolinski

PDL BioPharma, Inc. (NASDAQ:PDLI) Logo

Sentiment for PDL Biopharma Inc (NASDAQ:PDLI)

PDL Biopharma Inc (NASDAQ:PDLI) institutional sentiment decreased to 0.63 in 2018 Q2. Its down -0.15, from 0.78 in 2018Q1. The ratio worsened, as 47 investment professionals increased and started new stock positions, while 75 decreased and sold their stock positions in PDL Biopharma Inc. The investment professionals in our partner’s database now possess: 122.39 million shares, down from 129.11 million shares in 2018Q1. Also, the number of investment professionals holding PDL Biopharma Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 24 Reduced: 51 Increased: 27 New Position: 20.

PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company has market cap of $373.68 million. The firm operates through two divisions, Income Generating Assets and Product Sales. It currently has negative earnings. The Income Generating Assets segment consists of royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri; and notes and other long-term receivables, royalty rights, hybrid notes/royalties receivable, and equity investments in healthcare companies.

The stock increased 0.78% or $0.02 during the last trading session, reaching $2.57. About 443,414 shares traded. PDL BioPharma, Inc. (NASDAQ:PDLI) has declined 27.33% since October 2, 2017 and is downtrending. It has underperformed by 42.95% the S&P500.

Analysts await PDL BioPharma, Inc. (NASDAQ:PDLI) to report earnings on November, 1. They expect $0.07 EPS, down 50.00 % or $0.07 from last year’s $0.14 per share. PDLI’s profit will be $10.18 million for 9.18 P/E if the $0.07 EPS becomes a reality. After $0.10 actual EPS reported by PDL BioPharma, Inc. for the previous quarter, Wall Street now forecasts -30.00 % negative EPS growth.

Kestrel Investment Management Corp holds 1.36% of its portfolio in PDL BioPharma, Inc. for 1.59 million shares. West Family Investments Inc. owns 338,141 shares or 0.2% of their US portfolio. Moreover, Rocky Mountain Advisers Llc has 0.12% invested in the company for 14,300 shares. The Missouri-based Kennedy Capital Management Inc. has invested 0.08% in the stock. Connor Clark & Lunn Investment Management Ltd., a British Columbia – Canada-based fund reported 5.68 million shares.

Another recent and important PDL BioPharma, Inc. (NASDAQ:PDLI) news was published by Seekingalpha.com which published an article titled: “SevenSaoi Capital delivers letter to the board of PDL Biopharma” on September 20, 2018.

PDL BioPharma, Inc. (NASDAQ:PDLI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>